【Welfare News】 Yonsei University College of Medicine and the Milner Therapeutics Institute (Milner Institute) in Cambridge, UK, held an online’Korean-English AI Drug Development and Target Discovery Symposium’ through video conferencing platform on the 22nd and 24th of last month. did.
The symposium, which was enrolled by 450 people, was held to invite 10 experts in the development of artificial intelligence drugs from both Korea and the United Kingdom to in-depth discuss the current status and prospects of the development of treatments using artificial intelligence.
In particular, the discussion focused on how artificial intelligence is being introduced in the process of discovering target proteins and finding candidates for treatment, which are the initial stages of new drug development.
Clinical trials based on artificial intelligence and cases of post-marketing pharmacovigilance were also introduced, conveying the role of artificial intelligence throughout the entire course of drug development in a balanced manner from various angles.
Professor Jeong Jae-ho of the Department of Surgery at Yonsei University School of Medicine, who led the symposium, said, “Through academic communication and exchange of research results between a group of artificial intelligence drug development experts between Korea and the United Kingdom, we have taken the first step toward advancing the development of next-generation new drugs and presenting a new paradigm. In the future, we hope that it will be an opportunity to further revitalize science and technology exchanges between the two countries and contribute to solving human diseases and promoting health by jointly cooperating in the development of artificial intelligence technologies related to new drugs.”
Professor Yoo-Rang Park of the Department of Biomedical System Information at Yonsei University College of Medicine, who joined the symposium as a lecturer on the 24th, shared the results of the development of an artificial intelligence model related to side effects of anticancer drugs based on data from a multi-center hospital information system in Korea.
This symposium was held as part of the Korea-English Focal Point Project, which the Ministry of Science and ICT supports for researcher exchange activities and promotion of science and technology cooperation between Korea and the UK.
The Milner Institute, which co-hosted the symposium, is a laboratory affiliated with the University of Cambridge University School of Medicine and was established in 2015 to contribute to the development of new treatments using new research methodologies such as open artificial intelligence.
